286 related articles for article (PubMed ID: 11142175)
1. [A combination phase I/II study--dose escalation plan].
Yamamoto N
Gan To Kagaku Ryoho; 2000 Dec; 27(14):2267-74. PubMed ID: 11142175
[TBL] [Abstract][Full Text] [Related]
2. Adaptive design may hasten clinical trials.
Schmidt C
J Natl Cancer Inst; 2007 Jan; 99(2):108-9. PubMed ID: 17227993
[No Abstract] [Full Text] [Related]
3. New paradigm in dose-finding trials: patient-specific dosing and beyond phase I.
Rogatko A; Babb JS; Tighiouart M; Khuri FR; Hudes G
Clin Cancer Res; 2005 Aug; 11(15):5342-6. PubMed ID: 16061846
[TBL] [Abstract][Full Text] [Related]
4. [Phase I clinical trial design of anticancer agents--a Fibonacci and a modified Fibonacci sequence].
Kusaba H; Tamura T
Gan To Kagaku Ryoho; 2000 May; 27(5):775-8. PubMed ID: 10832451
[TBL] [Abstract][Full Text] [Related]
5. Design issues in dose-finding Phase I trials for combinations of two agents.
Fan SK; Venook AP; Lu Y
J Biopharm Stat; 2009; 19(3):509-23. PubMed ID: 19384692
[TBL] [Abstract][Full Text] [Related]
6. Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method.
Normolle D; Lawrence T
J Clin Oncol; 2006 Sep; 24(27):4426-33. PubMed ID: 16983110
[TBL] [Abstract][Full Text] [Related]
7. [Accelerated titration design].
Minami H
Gan To Kagaku Ryoho; 2000 Sep; 27(10):1601-7. PubMed ID: 11016010
[TBL] [Abstract][Full Text] [Related]
8. [Combined antineoplastic agents guidelines--guidelines for clinical trials I/II].
Gan To Kagaku Ryoho; 2004 Apr; 31(4):657-65. PubMed ID: 15114719
[No Abstract] [Full Text] [Related]
9. [Methodological approaches of clinical studies with targeted therapies].
Penel N; Saleron J; Lansiaux A; Clisant S; Adenis A; Fournier C; Duhamel A; Bonneterre J
Bull Cancer; 2008 Feb; 95(2):185-90. PubMed ID: 18304903
[TBL] [Abstract][Full Text] [Related]
10. Choice of designs and doses for early phase trials.
Zhou Y
Fundam Clin Pharmacol; 2004 Jun; 18(3):373-8. PubMed ID: 15147290
[TBL] [Abstract][Full Text] [Related]
11. Three-dose-cohort designs in cancer phase I trials.
Huang B; Chappell R
Stat Med; 2008 May; 27(12):2070-93. PubMed ID: 17764082
[TBL] [Abstract][Full Text] [Related]
12. Dose-escalation models for combination phase I trials in oncology.
Hamberg P; Ratain MJ; Lesaffre E; Verweij J
Eur J Cancer; 2010 Nov; 46(16):2870-8. PubMed ID: 20691584
[TBL] [Abstract][Full Text] [Related]
13. Optimal phase I dose-escalation trial designs in oncology--a simulation study.
Gerke O; Siedentop H
Stat Med; 2008 Nov; 27(26):5329-44. PubMed ID: 17849502
[TBL] [Abstract][Full Text] [Related]
14. [Phase I cancer trials methodology].
Le Tourneau C; Faivre S; Raymond E; Diéras V
Bull Cancer; 2007 Nov; 94(11):943-51. PubMed ID: 18055311
[TBL] [Abstract][Full Text] [Related]
15. Optimal designs for estimating the most successful dose.
Zohar S; O'Quigley J
Stat Med; 2006 Dec; 25(24):4311-20. PubMed ID: 16969893
[TBL] [Abstract][Full Text] [Related]
16. [The strategy of combination phase I/II study].
Murakami H; Ohe Y; Saijo N
Gan To Kagaku Ryoho; 2000 Nov; 27(13):2151-4. PubMed ID: 11103251
[TBL] [Abstract][Full Text] [Related]
17. Phase II clinical trials in oncology: are we hitting the target?
Ang MK; Tan SB; Lim WT
Expert Rev Anticancer Ther; 2010 Mar; 10(3):427-38. PubMed ID: 20214523
[TBL] [Abstract][Full Text] [Related]
18. Risks and benefits associated with novel phase 1 oncology trial designs.
Koyfman SA; Agrawal M; Garrett-Mayer E; Krohmal B; Wolf E; Emanuel EJ; Gross CP
Cancer; 2007 Sep; 110(5):1115-24. PubMed ID: 17628485
[TBL] [Abstract][Full Text] [Related]
19. New designs for phase II trials: application to a trial of targeted therapies vs. chemotherapy in patients age > 60 with AML/high-risk MDS.
Estey EH
Ann Hematol; 2004; 83 Suppl 1():S94-6. PubMed ID: 15124692
[No Abstract] [Full Text] [Related]
20. Designs for single- or multiple-agent phase I trials.
Conaway MR; Dunbar S; Peddada SD
Biometrics; 2004 Sep; 60(3):661-9. PubMed ID: 15339288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
